{"id":37324,"date":"2016-07-25T11:04:28","date_gmt":"2016-07-25T15:04:28","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37324"},"modified":"2016-07-25T11:04:28","modified_gmt":"2016-07-25T15:04:28","slug":"exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324","title":{"rendered":"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Exelixis, Inc. (NASDAQ:EXEL)<\/strong> and <strong>Ipsen SA (EPA:IPN)\u00a0<\/strong>have a new phase of development for their Cabometyx\u2122 (cabozantinib). The treatment that comes in 20, 40, and 60mg a which is use in the treatment of advanced renal cell carcinoma (RCC) in adults has received positive recommendation from Committee for Medicinal Products for Human Use (CHMP). The recommendation was also backed up by the scientific committee of the European Medicines Agency (EMA) for marketing purposes.<\/p>\n<p style=\"text-align: justify;\">Speaking about the long-awaited approval, Chief Executive Officer of Ipsen, David Meek expressed the company\u2019s enthusiasm calling it a significant milestone for both Exelixis and Ipsen. The treatment will be use in patients with advanced renal cell carcinoma but who must have received one prior therapy. The achievement is a shared undertaking by the two companies in delivering modern treatments to advance the treatment of cancer that has become a threat to many households.<\/p>\n<p style=\"text-align: justify;\"><strong>More about the Recommendation from CHMP and EMA<\/strong><\/p>\n<p style=\"text-align: justify;\">The two bodies are entrusted with reviewing and giving approvals to medicinal products that are expected to be part of a major public. This particular recommendation means that the rug has met the terms and conditions that the bodies consider being of public interest and especially in addressing a serious unmet medical need.<\/p>\n<p style=\"text-align: justify;\">The validation of Exelixis\u2019 Marketing Authorization Application (MAA) for Cabometyx gives it 150-day review legibility by the European Commission which has an upper hand in approving medicines in over 28 countries of the European Union. Recommendations for use of the product shall then be described in the Summary of Product Characteristics (SmPC).<\/p>\n<p style=\"text-align: justify;\"><strong>What should be known about the METEOR Phase 3 Pivotal Trial?<\/strong><\/p>\n<p style=\"text-align: justify;\">That it met its primary endpoint of significantly improving PFS having been carried out at about 200 sites across 26 countries. Patients were randomized 1:1 to receive a daily dose of 60 mg of Cabometyx. The Secondary endpoints had everything to do with OS and objective reaction rate in all patients who were enrolled from Western Europe, North America, and Australia<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Exelixis, Inc. (NASDAQ:EXEL) and Ipsen SA (EPA:IPN)\u00a0have a new phase of development for their Cabometyx\u2122 (cabozantinib). The treatment that comes in 20, 40, and 60mg [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":37325,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11937,8676,5579,5580,11936,11935],"stock_ticker":[],"class_list":["post-37324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-epaipn","tag-exelixis-inc","tag-exelixis-inc-nasdaqexel","tag-nasdaqexel","tag-psen-sa","tag-psen-sa-epaipn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Exelixis, Inc. (NASDAQ:EXEL) and Ipsen SA (EPA:IPN)\u00a0have a new phase of development for their Cabometyx\u2122 (cabozantinib). The treatment that comes in 20, 40, and 60mg [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-25T15:04:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx\",\"datePublished\":\"2016-07-25T15:04:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg\",\"keywords\":[\"EPA:IPN\",\"Exelixis Inc.\",\"Exelixis Inc. (NASDAQ:EXEL)\",\"NASDAQ:EXEL\",\"psen SA\",\"psen SA (EPA:IPN)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\",\"name\":\"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg\",\"datePublished\":\"2016-07-25T15:04:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg\",\"width\":300,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324","og_locale":"en_US","og_type":"article","og_title":"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx - Wall Street PR","og_description":"Exelixis, Inc. (NASDAQ:EXEL) and Ipsen SA (EPA:IPN)\u00a0have a new phase of development for their Cabometyx\u2122 (cabozantinib). The treatment that comes in 20, 40, and 60mg [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2016-07-25T15:04:28+00:00","og_image":[{"width":300,"height":200,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx","datePublished":"2016-07-25T15:04:28+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg","keywords":["EPA:IPN","Exelixis Inc.","Exelixis Inc. (NASDAQ:EXEL)","NASDAQ:EXEL","psen SA","psen SA (EPA:IPN)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324","url":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324","name":"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg","datePublished":"2016-07-25T15:04:28+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/Exelixis-Inc.jpg","width":300,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exelixis-inc-nasdaqexel-and-ipsen-sa-epaipn-gain-approval-of-their-cabometyx-37324#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Exelixis, Inc. (NASDAQ:EXEL) And Ipsen SA (EPA:IPN) Gain Approval Of Their Cabometyx"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37324"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37324\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37325"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37324"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}